Research

LIke ThisLIke ThisLIke This

Soumitro Pal, PhD

Soumitro Pal, PhD
Research Center:
Transplant Research Program
Division
Nephrology Research
Hospital Title:
Research Associate
Academic Title:
Assistant Professor of Pediatrics, Harvard Medical School
Research Focus Area:
Transplant ImmunologyPost-transplantation cancer
Contact:
617-919-2989
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Dr. Pal's laboratory is focused on studying the mechanism of renal injury, renal inflammation and renal cancer, with particular importance paid to the signal transduction pathways regulating gene expression. One of the main focuses of Dr. Pal's research is to identify molecular mechanisms of cancer growth in patients receiving organ transplants. For instance, it has been shown that although calcineurin inhibitors (CNI) are very good immunosuppressive agents, they can promote cancer, while the mTOR inhibitor rapamycin (RAPA) can inhibit cancer growth. Dr. Pal's work has demonstrated that treatment with CNI can activate the Ras-Raf-Nrf2-HO-1 signaling cascade, which plays a critical role in renal cancer growth. Dr. Pal has developed a sophisticated murine model to study the mechanism of post-transplantation cancer growth. Dr. Pal's research aims to identify molecular targets to develop novel drugs for the treatments of renal inflammation and cancer.

About Soumitro Pal

Dr Pal received his Ph.D. in Physiology from University of Calcutta. He did his post-doctoral research in the field of angiogenesis at Beth Israel Deaconess Medical Center and Harvard Medical School.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Basu A, Banerjee P, Pal S. Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression. Cell Cycle. 2012 Feb 15; 11(4):633-4.
  2. Basu A, Liu T, Banerjee P, Flynn E, Zurakowski D, Datta D, Viklicky O, Gasser M, Waaga-Gasser AM, Yang J, Pal S. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett. 2012 Aug 28; 321(2):179-86.
  3. Basu A, Banerjee P, Contreras AG, Flynn E, Pal S. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One. 2011; 6(8):e23919.
  4. Basu A, Datta D, Zurakowski D, Pal S. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem. 2010 Aug 13; 285(33):25196-202.
  5. Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, Pal S. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 2009 Dec 1; 69(23):8902-9.
  6. Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM. mTOR-understanding the clinical effects. Transplant Proc. 2008 Dec; 40(10 Suppl):S9-S12.
  7. Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol. 2008 Dec; 19(12):2437-46.
  8. Briscoe DM, Pal S. Assessing the vascular effects of early erythropoietin use in pediatric renal transplant recipients. Nat Clin Pract Nephrol. 2008 Mar; 4(3):136-7.
  9. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006 Oct 1; 66(19):9509-18.
  10. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol. 2006 Mar 1; 176(5):3098-107.
  11. Show all
  12. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol. 2004 Jun 15; 172(12):7503-9.
  13. Neid M, Datta K, Stephan S, Khanna I, Pal S, Shaw L, White M, Mukhopadhyay D. Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem. 2004 Feb 6; 279(6):3941-8.
  14. Basu A, Basu I, Chakraborty A, Pal S, Chattopadhyay U. Detection and purification of a novel 72 kDa glycoprotein male breast tumor associated antigen. Int J Cancer. 2003 Jun 20; 105(3):377-83.
  15. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 2001 Sep 15; 61(18):6952-7.
  16. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001 May; 7(5):569-74.
  17. Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay D, Briscoe DM. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000 Dec 1; 96(12):3801-8.
  18. Pal S, Datta K, Khosravi-Far R, Mukhopadhyay D. Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J Biol Chem. 2001 Jan 26; 276(4):2395-403.
  19. Pal S, Iruela-Arispe ML, Harvey VS, Zeng H, Nagy JA, Dvorak HF, Mukhopadhyay D. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc Res. 2000 Sep; 60(2):112-20.
  20. Ghosh S, Pal S, Das S, Dasgupta SK, Majumdar S. Lipoarabinomannan induced cytotoxic effects in human mononuclear cells. FEMS Immunol Med Microbiol. 1998 Jul; 21(3):181-8.
  21. Pal S, Sanyal U, Chattopadhyay U. Purification and characterization of a new 85-kDa glycoprotein antigen from human breast tumor. Int J Cancer. 1995 Mar 16; 60(6):759-65.
  22. Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM. Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol. 2010 Jan 15; 184(2):545-9.
  23. Pal S, Claffey KP, Cohen HT, Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem. 1998 Oct 9; 273(41):26277-80.
  24. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem. 1997 Oct 31; 272(44):27509-12.
  25. Banerjee P, Basu A, Datta D, Gasser M, Waaga-Gasser AM, Pal S. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J Biol Chem. 2011 Sep 23; 286(38):33580-90.
  26. Datta D, Dormond O, Basu A, Briscoe DM, Pal S. Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007 Oct; 293(4):F1222-30.
  27. Laxmanan S, Datta D, Geehan C, Briscoe DM, Pal S. CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol. 2005 Sep; 16(9):2714-23.
  28. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem. 2000 Jul 7; 275(27):20700-6.
  29. Lapchak PH, Melter M, Pal S, Flaxenburg JA, Geehan C, Frank MH, Mukhopadhyay D, Briscoe DM. CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island. Am J Physiol Renal Physiol. 2004 Sep; 287(3):F512-20.
  30. Banerjee P, Basu A, Wegiel B, Otterbein LE, Mizumura K, Gasser M, Waaga-Gasser AM, Choi AM, Pal S. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J Biol Chem. 2012 Sep 14; 287(38):32113-23.
  31. Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 2008 Jul 15; 68(14):5689-98.
  32. Bruneau S, Datta D, Flaxenburg JA, Pal S, Briscoe DM. TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor. Biochem Biophys Res Commun. 2012 Mar 2; 419(1):66-71.
  33. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe DM. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol. 2008 Dec 1; 181(11):8088-95.
  34. Datta D, Banerjee P, Gasser M, Waaga-Gasser AM, Pal S. CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem. 2010 Nov 19; 285(47):36842-8.
  35. Banerjee P, Basu A, Arbiser JL, Pal S. The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett. 2013 Sep 28; 338(2):292-9.
  36. Balan M, Pal S. A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem. 2014 Feb 7; 289(6):3126-37.
  37. Medvetz D, Sun Y, Li C, Khabibullin D, Balan M, Parkhitko A, Priolo C, Asara JM, Pal S, Yu J, Henske EP. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting. Mol Cancer Res. 2015 Jan; 13(1):50-62.
  38. Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015 Mar 27; 290(13):8110-20.
LIke ThisLIke ThisLIke This

RELATED RESEARCH CENTER

Transplant Research Program


Learn more
Close